UVAX 1197
Alternative Names: UVAX-1197Latest Information Update: 02 Feb 2024
At a glance
- Originator The Scripps Research Institute
- Developer Uvax Bio
- Class AIDS vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I HIV-1 infections
Most Recent Events
- 30 Jan 2024 Phase-I clinical trials in HIV-1 infections (Prevention) in Australia (IM) (ACTRN12624000064505)
- 19 Dec 2023 Uvax Bio plans a phase I trial for HIV-1 infections (Prevention) in Australia in January 2024
- 19 Dec 2023 Human Research Ethics Committee (HREC) of Australian Therapeutic Goods Administration approves a clinical trial application for UVAX-1197 to initiate a phase I trial in HIV-1 infections (Prevention) in Australia